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ABSTRACT (n = 109) 
The GRAPPA-OMERACT Psoriatic Arthritis (PsA) working group is in the process of updating 
the PsA core domain set to improve and standardize the measurement of PsA outcomes.  Work 
streams comprise literature reviews of domains and outcome measurement instruments, an 
international qualitative research project with PsA patients to generate domains important to 
patients, outcome measurement instrument assessment, conduct of domain consensus panels 
with patients and physicians, and evidence-based selection of instruments.  Patient Research 
Partners are involved in each of the projects.  The working group will present findings and seek 
endorsement for the new PsA core domain set, outcome measurement set, and research 
agenda at the OMERACT Meeting in May 2016. 
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INTRODUCTION 
 In order to standardize measurements of disease used in randomized clinical trials, 
disease-specific groups within the Outcome Measures in Rheumatology organization 
(OMERACT) have developed Core Domain Sets and Core Outcome Measurement Sets.  A 
Core Outcome Measurement Set defines the minimum measurements that should be collected 
in randomized controlled trials (RCTs) as well as other studies to inform patients, physicians, 
and other stakeholders about the status of patients and the efficacy of medication.  The core set 
is recommended for RCTs, and is applicable to longitudinal observational studies and to clinical 
practice.  Before developing a Core Outcome Measurement Set, working groups must first 
define the “domains” or constructs of most interest to stakeholder groups, i.e., the Core Domain 
Set.  Then measurement instruments can be identified and assessed for each domain.  
OMERACT published specific methodological standards and step-by-step recommendations to 
guide disease-specific groups in drafting disease-specific core sets, which could then achieve 
multi-stakeholder consensus at OMERACT meetings.(1, 2) 
 The existing psoriatic arthritis (PsA) core domain set for clinical trials, endorsed at the 
OMERACT meeting in 2006, contains the following domains:  peripheral joint activity, skin 
activity, patient global, pain, physical function, and health-related quality of life.(3)  Since the 
endorsement of the 2006 PsA Core Set,(3, 4) new PsA outcome measures for clinical trials and 
clinical care have been developed.  Patient Research Partners (PRPs) have been included in 
evaluating the completeness of the core set (4-6) and development of measures.(7)  
Additionally, OMERACT has developed a new “Filter 2.0” framework, which outlines four core 
areas to be covered in each core set.  These core areas are relevant across all health 
conditions and need to be matched with disease-specific domains.(2)  The PsA OMERACT 
Working Group is now updating the PsA core domain set with these objectives: 1) increase 
patient involvement in elaboration of the core set, and 2) integrate the use of the OMERACT 
Filter 2.0 methodology, adopted in 2014.(2, 8) 
 The United Kingdom (UK) is leading a synergistic initiative where focus groups will be 
conducted within the “early detection to imPRove OutcoMe in people with undiagnosed Psoriatic 
arthriTis” (PROMPT) programme.  PROMPT will determine whether early detection improves 
outcome in patients with undiagnosed PsA and will ensure that outcome measures encompass 
aspects of early disease.  Focus groups will be held to identify the outcomes important to PsA 
patients.  Outcomes will then be ranked by patients and mapped with the existing core set of 
domains and composite measures of disease to identify omissions within both.  Finally, existing 
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patient-reported outcome measures will be identified to address these omissions and inform 
revised full and shortened versions of composite measures.  A follow-up study within PROMPT, 
assessment of modified COMPosite disease meAsures in REcently diagnosed PsA 
(COMPARE), will validate these modified composite measures. 
 As summarized in this report, the PsA Working Group has made significant progress 
toward their objectives since the May 2014 OMERACT meeting. 
PLENARY PRESENTATIONS 
 Four plenary presentations were made at the 2015 annual meeting of the Group for 
Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): 1) an overview of the 
multiple ongoing projects aimed at achieving patient and clinician consensus on preliminary PsA 
core sets of domains and outcome measures (Figure 1); 2) a summary of the development of 
the patient-derived and disease-specific PsA Impact of Disease (PsAID) (9) outcome measure; 
3) a presentation of the generic Patient Reported Outcomes Measurement Information System 
(PROMIS®) measures and applicability to PsA; and 4) a patient and clinician focus group project 
in the United States (US) that identifies how patients and physicians prioritize PsA domains and 
asks patients about the content validity of PsA outcome measures. 
 
1. Overview of GRAPPA-OMERACT PsA Working Group activities 
 Drs. Ana-Maria Orbai, Alexis Ogdie, and Umut Kalyoncu presented the framework, 
timeline, activities, and preliminary results from the working group.  Ongoing projects include 
1) two systematic literature reviews (SLR); 2) conduct of international focus groups; 3) outcome 
measures assessment in clinical trial datasets; and two domain prioritization projects: 4) Delphi 
exercises separately with patients and physicians; and 5) a face-to-face nominal group 
technique consensus meeting with both patients and physicians.  At least two PRPs are 
involved in each work stream and a total of five PRPs are part of the working group. The PsA 
working group also includes two fellows who will be actively involved in conducting the outcome 
measure literature review, and coordinating the consensus process.  Projects are outlined 
below. 
1) Systematic Literature Reviews 
 Systematic Literature Review 1.  In addition to the existing SLR of outcomes measured 
in PsA RCTs from 2006 to 2010,(10) an SLR of PsA RCTs from 2010 to 2015 is ongoing (SLR1) 
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to generate lists of domains and outcome measures.  We presented preliminary results of 
SLR1.  Most of the domains identified in PsA RCTs mapped not only to the existing 2006 PsA 
core set domains (3) but also to other domains such as “Resource Use,” a core area under the 
OMERACT Filter 2 framework.(2)  Some clinical trial domains mapped to more than one core 
area, e.g., “patient global” mapped to both pathophysiologic manifestations and life impact and 
“productivity” to both life impact and resource use.  The SLR1 will be expanded to include data 
from longitudinal observational studies.  Further, any additional domains identified from the 
PsAID outcome measure,(9) previous International Classification of Functioning PsA mapping 
studies,(11, 12) and the ongoing PsA Flare study (13) will also be included to generate a 
comprehensive list of candidate domains for the updated PsA core domain set. 
 Systematic Literature Review 2.  This second SLR (SLR2) will focus specifically on 
psychometric properties of outcome measures.(14)  The objective is to synthesize data on 
truth/validity, feasibility, discrimination, availability of meaningful cutoffs, and patient involvement 
for each PsA outcome measure.(2)  SLR2 will follow methodology developed by the 
Consensus-based Standards for the selection of health Measurement Instruments (COSMIN) 
group to identify all available studies on the measurement properties of all available outcome 
measures in PsA.(15, 16)  Using the COSMIN checklist for critical appraisal of the measurement 
properties of each outcome measure will reveal any potential gaps among existing instruments 
and the need to revise or develop new outcome measurement instruments. 
2) Qualitative Research.   
 A multi-national qualitative research project is ongoing in seven countries with two focus 
groups in each country (US, Netherlands, Australia, Brazil, Canada, France, and Singapore) 
and five to eight patients in each focus group.  The objective is to determine domains of greatest 
importance to patients with PsA.  Qualitative data will be translated into English and analyzed by 
a core qualitative research team from the US and the Netherlands with input from all 
investigators and PRPs.  Domains identified in focus groups with PsA patients will be added to 
the comprehensive list of candidate domains, which will be subject to Delphi rounds and 
nominal group technique meeting (below), for the updated PsA core set. 
3) Outcome Measurement Instrument Assessment.   
 A thorough assessment of available outcome measures to measure candidate core 
domains in PsA is also underway.  Clinical trial datasets have been requested from five 
pharmaceutical companies for the purpose of assessing outcome measure content and 
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construct validity.  This will determine additional domains to be included in the Delphi 
procedures, a draft set of candidate outcome measures, and subsequent steps required to 
identify candidate responder index/indices. 
4) Delphi Exercises to Narrow Candidate Domains.   
 A single comprehensive list of domains will be created by merging domains identified 
through the aforementioned work streams.  This list will be discussed with PRPs and 
subsequently the entire PsA working group.  The discussion with PRPs will center on face 
validity and completeness of the initial domain list, redundancy, and inclusion of missing 
domains as needed.  The final draft list of domains will be the basis for two parallel domain-
ranking Delphi exercises with patients and rheumatologists, using a web-based platform.  
Diverse international representation will be ensured, with 100 participants in each group.  PRPs 
will help to evaluate and optimize comprehensibility for the patient Delphi, using up to three 
rounds of surveys.   At the conclusion of the Delphi rounds, the most highly ranked domains will 
be shown on two lists, one each from patients and physicians. 
5) Consensus meeting with patients and healthcare providers.  
 A face-to-face consensus meeting including 12 patients and 12 rheumatologists is 
planned for mid-March 2016.  The meeting will be moderated by a methodologist not involved in 
the working group and using a modified nominal group technique to ensure there is no bias in 
including both the PRP and rheumatologist perspectives.  The objective of the meeting is to 
reconcile the two domain lists and to define a preliminary core domain set for presentation, 
consensus, and endorsement at the OMERACT meeting in May 2016. 
 
2. Psoriatic Arthritis Impact of Disease (PsAID) 
 Dr. Laure Gossec presented the development and validation of the European League 
against Rheumatism (EULAR) PsAID outcome measure.(9)  The PsAID was patient-derived 
with active involvement of patients on different levels.(7)  Domains were identified by PRPs from 
11 European countries who participated in a meeting to prioritize PsA health domains.  These 
domains were then subject to prioritization by 139 patients to exclude the four lowest prioritized 
domains of the initial 16 domains.  There are two versions of the PsAID questionnaire:  one with 
12 domains recommended for clinical care, and one with nine domains recommended for 
clinical trials.  The PsAID was validated in a sample of 447 people with PsA from different 
European countries.  The relation with other well-known outcome measures was evaluated 
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cross-sectionally, and reliability and sensitivity to change in smaller samples was validated 
longitudinally (N=80 and 71, respectively).  The measures appeared to perform well, and 
reliability was high (ICC=0.95, 95%CI 0.92-0.96). The PsAID questionnaires are free to use and 
available from the EULAR website in several languages 
(http://www.eular.org/tools_products.cfm).  External validation is ongoing. 
 
3. Patient Reported Outcomes Measurement Information System (PROMIS®) 
 Dr. Ana-Maria Orbai summarized the steps and methodology used in the development of 
the Patient Reported Outcomes Measurement Information System (PROMIS®).  PROMIS, 
developed with US National Institutes of Health support, is a library of generic health measures 
meant to be used across chronic health conditions.  PROMIS uses state-of-the-art qualitative, 
quantitative, and psychometric methodology from health concept definition to outcome measure 
testing and validation in a large US population sample (n=21,000).  Each item was tested in 
about 900 people from the general population and 500 people living with a chronic disease.  
PROMIS measures are free to use (http://assessmentcenter.net) and are being translated and 
validated in multiple languages by the PROMIS International organization.(17, 18)  PROMIS 
measure implementation and expansion is currently focused on validation studies in specific 
health conditions,(19-23) including testing in PsA in an ongoing longitudinal project at Johns 
Hopkins.(24) 
 
4. Project Focus Groups with Patients and Physicians 
 Dr. Philip Mease presented the plan for a US multicenter qualitative study to identify how 
patients and physicians prioritize health domains in PsA.  A second objective is to examine 
patient perceptions of outcome measures that are either currently being used or are candidate 
measures for use in PsA clinical trials.  The project addresses the content validity of these 
measures and will inform outcome measure selection for the PsA core outcome measurement 
instrument set. 
 
DISCUSSION 
 An update of the 2006 PsA Core Domain Set is underway to ensure that it incorporates 
the patients’ perspectives and reflects the subsequent accumulated knowledge in the PsA field.  
For example, we now have a better understanding of patient preferences and priorities from 
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development of new outcome measures for PsA as well as PsA pathophysiology since the 
discovery and approval of new therapeutics.  Researchers in the GRAPPA-OMERACT PsA 
working group are using OMERACT Filter 2.0 methodology (2, 8, 25) to build on prior work 
through SLRs and secondary data analyses of outcome measures used in clinical trial datasets.   
The qualitative research work stream with PsA patients is pivotal in eliciting concepts of 
importance to patients and ensuring PsA assessments are based on a valid and complete 
conceptual framework for PsA domains.  Equal input from patients and healthcare providers in 
deciding on core domains through Delphi and consensus meeting components is essential 
because their priorities complement each other.  This is exemplified by the OMERACT 2006 
patient perspective workshop (26) and the Rheumatoid Arthritis (RA) Flare Delphi exercises (27) 
where PRP participation led to the inclusion of fatigue in RA assessments and of additional 
domains for RA flare assessment.  The findings in RA parallel the evolution of PsA data related 
to fatigue, where fatigue was the third most important domain prioritized by patients (after pain 
and skin) in the PsAID questionnaire,(9) but has yet to be included in the current PsA core 
domain set.  This situation may be similar for other PsA domains.  Concurrently, PsA outcome 
measurement instruments are being evaluated for their completeness as well as fulfillment of 
OMERACT Filter 2.0 standards. 
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Figure 1. Timeline of the GRAPPA OMERACT Psoriatic Arthritis Working Group Activities 
 
 
 
 
